Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action
PR Newswire —
(NASDAQ: RGNX) NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Regenxbio Inc. (NASDAQ: RGNX) regarding potential gaps between information provided to investors and underlying safety developments in the company's gene therapy clinical programs. Shareholders...